Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.21.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Operating expenses:    
Research and development $ 1,206,779 $ 344,407
General and administrative 687,936 791,607
Total operating expenses 1,894,715 1,136,014
Loss from operations (1,894,715) (1,136,014)
Other income:    
Interest income 10,696 45,137
Net loss (1,884,019) (1,090,877)
Other comprehensive income (loss):    
Foreign currency translation gain (loss) 2,774 (4,041)
Comprehensive loss $ (1,881,245) $ (1,094,918)
Net loss per share:    
Basic and diluted $ (0.16) $ (0.10)
Weighted average shares outstanding:    
Basic and diluted 12,139,422 10,608,199